Navigation Links
Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Date:6/18/2013

product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and jud
'/>"/>
SOURCE Newron Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
3. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
4. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
7. NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinsons Disease and Movement Disorders
8. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
9. Generex Announces Interview of MD Andersons Dr. Elizabeth Mittendorf, Principal Investigator on Companys AE37 Phase IIb Breast Cancer Efficacy Trial
10. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
11. SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014  Advanced Medical Isotope Corporation ... engaged primarily in the development of brachytherapy devices ... today announced that a Life Sciences Discovery Fund ... for which AMIC is the commercialization partner.  The ... for the proposal titled "Optimized Injectable Radiogels for ...
(Date:12/19/2014)... 2014 In today,s increasingly global marketplace ... to reflect the needs of a global marketplace ... the needs of key stakeholders while recognizing regional ... According to recent research by benchmarking firm, Best ... companies averaged more than $100,000 in annual spending ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Building a Best-in-Class Pharma Global Brand Website 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... Shire plc (LSE: SHP,NASDAQ: SHPGY ), the ... pending litigation with Sandoz, Inc. ("Sandoz") in,connection with Sandoz,s ... generic versions of Shire,s ADDERALL XR(R) (mixed,amphetamine salts) for ... The settlement also provides Sandoz with a ...
... Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced ... of Patrick J. McEnany,s employment agreement with the Company ... , The Company announced that Steven R. Miller, ... Dr. Miller, currently Catalyst,s Vice President, Pharmaceutical Development ...
Cached Medicine Technology:Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R) 2Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R) 3Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executive's Employment Agreement 2Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executive's Employment Agreement 3
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare transformation, ... Yarrington as Vice President of Operations, Adam Wallace as ... President of Solutions. These new leaders are part of ... to support client demand for the company’s big data ... of its partner network. , Since the company ...
(Date:12/22/2014)... Give a loved one the greatest gift of ... vitality. , For a limited time, HealthiPlus ( https://healthiplus.com/christmas-gift-packages/ ... special Holiday Wellness gift packages at drastically reduced prices ... contains cutting-edge, proven nutritional support for joints, mental functioning ... we age. , Joint Health Plus contains ...
(Date:12/22/2014)... December 22, 2014 The MedTech industry is ... a wholly owned subsidiary of PartnerTech AB of Sweden, is ... recently achieved additional ISO Certification. , All signs point to ... and the likelihood of a repeal of the excise tax ... The industry is anticipating annual growth of 9.3% and PartnerTech ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
(Date:12/22/2014)... December 22, 2014 TheHardwareCity.com now stocks ... with many useful features. Customers of the large online ... the new gloves delivered to their home or workplace ... hand tools that incorporate heavy duty magnets, which make ... allows workers to store metal parts on the back ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... Blue Cross Blue Shield of Michigan has,been named 2007 ... Michigan,Minority Business Development Council., The award recognizes the ... of suppliers to the corporation., "Blue Cross Blue ... because it recognizes our strong commitments to diversity and ...
... infants make distinctions based on behaviors , , WEDNESDAY, Nov. 21 (HealthDay ... learned language can still judge who is friend and who is ... who cooperate versus people who hurt, and this ability could be ... the Yale researchers. Their study is published in the Nov. 22 ...
... Susan G. Komen for the Cure, the,nation,s ... research and,community-based outreach programs, is accepting applications to ... a,parent to breast cancer., (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ... students cover the costs of,tuition, books, fees and ...
... (Amex: IMA ), announced today that it closed ... a total,of 13,634,302 shares in the offering at a ... of shares sold by the Company included,1,800,000 shares sold ... in full. Certain selling stockholders of the Company,also sold ...
... widespread and often deadly among older American women, doctors ... to a new report by a team of vascular ... Cornell Medical College campuses of NewYork-Presbyterian Hospital. , Much ... years, cardiovascular research has focused almost exclusively on males, ...
... CITY, Calif., Nov. 21 Genomic Health,Inc. (Nasdaq: ... Ph.D., Genomic,Health,s Chairman and Chief Executive Officer, will ... New York, NY on November 28, 2007 at ... and subsequently archived webcast of the,presentation, visit the ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Named 2007 Corporation of the Year in Health Care by Michigan Minority Business Development Council 2Health News:Babies Can Tell Friend From Foe 2Health News:Susan G. Komen for the Cure Provides Scholarships for Students Who Lost a Parent to Breast Cancer 2Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 2
For the direct colorimetric determination of alkaline phosphatase in human serum....
Auto LDL-Cholesterol, automated analyzer test kits....
For the quantitative determination of uric acid in serum....
For the quantitative determination of uric acid in serum....
Medicine Products: